Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Research
Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Table of Contents

Breaking Advances

  • Breaking Advances
    Highlights from Recent Cancer Literature
    Cancer Res January 15 2011 71 (2) 291-292;

Reviews

  • Reviews
    Phospholipase D Meets Wnt Signaling: A New Target for Cancer Therapy
    Dong Woo Kang, Kang-Yell Choi and Do Sik Min
    Cancer Res January 15 2011 71 (2) 293-297; DOI:10.1158/0008-5472.CAN-10-2463

  • Reviews
    Physical Oncology: A Bench-to-Bedside Quantitative and Predictive Approach
    Hermann B. Frieboes, Mark A.J. Chaplain, Alastair M. Thompson, Elaine L. Bearer, John S. Lowengrub and Vittorio Cristini
    Cancer Res January 15 2011 71 (2) 298-302; DOI:10.1158/0008-5472.CAN-10-2676

Perspective

  • Perspective
    Cancer Cells Cut Homophilic Cell Adhesion Molecules and Run
    Sonya E.L. Craig and Susann M. Brady-Kalnay
    Cancer Res January 15 2011 71 (2) 303-309; DOI:10.1158/0008-5472.CAN-10-2301

Meeting Reports

  • Meeting Reports
    The First Tianjin, China Forum on Tumor Microenvironment
    Evan T. Keller and Lu-Yuan Li
    Cancer Res January 15 2011 71 (2) 310-313; DOI:10.1158/0008-5472.CAN-10-2930

  • Meeting Reports
    NCI Image-Guided Drug Delivery Summit
    Pushpa Tandon and Keyvan Farahani
    Cancer Res January 15 2011 71 (2) 314-317; DOI:10.1158/0008-5472.CAN-10-2629

Microenvironment and Immunology

  • Microenvironment and Immunology
    Heat Shock Protein 27 Differentiates Tolerogenic Macrophages That May Support Human Breast Cancer Progression
    Sanjib Banerjee, Chuen-Fu L. Lin, Kristin A. Skinner, Linda M. Schiffhauer, James Peacock, David G. Hicks, Eileen M. Redmond, David Morrow, Alissa Huston, Michelle Shayne, Howard N. Langstein, Carol L. Miller-Graziano, Jennifer Strickland, Lauren O'Donoghue and Asit K. De
    Cancer Res January 15 2011 71 (2) 318-327; DOI:10.1158/0008-5472.CAN-10-1778

    Findings define a novel immune escape mechanism supporting breast cancer growth which is mediated by a heat shock chaperone protein.

  • Microenvironment and Immunology
    Minimal Engagement of CD103 on Cytotoxic T Lymphocytes with an E-Cadherin-Fc Molecule Triggers Lytic Granule Polarization via a Phospholipase Cγ–Dependent Pathway
    Audrey Le Floc'h, Abdelali Jalil, Katarzyna Franciszkiewicz, Pierre Validire, Isabelle Vergnon and Fathia Mami-Chouaib
    Cancer Res January 15 2011 71 (2) 328-338; DOI:10.1158/0008-5472.CAN-10-2457

    This study defines a co-stimulatory signal for tumor-infiltrating T cells that is required along with T-cell receptor engagement to trigger cytolytic granule lysis of cancer cell targets.

Molecular and Cellular Pathobiology

  • Molecular and Cellular Pathobiology
    A Novel Transgenic Mouse Model of the Human Multiple Myeloma Chromosomal Translocation t(14;16)(q32;q23)
    Naoki Morito, Keigyou Yoh, Atsuko Maeda, Takako Nakano, Akiko Fujita, Manabu Kusakabe, Michito Hamada, Takashi Kudo, Kunihiro Yamagata and Satoru Takahashi
    Cancer Res January 15 2011 71 (2) 339-348; DOI:10.1158/0008-5472.CAN-10-1057

    A novel transgenic mouse model may offer an ideal system to study the pathogenesis of human multiple myeloma, an aggressive disease that remains relatively poorly managed.

  • Molecular and Cellular Pathobiology
    HMGA2 Overexpression-Induced Ovarian Surface Epithelial Transformation Is Mediated Through Regulation of EMT Genes
    Jingjing Wu, Zhaojian Liu, Changshun Shao, Yaoqin Gong, Eva Hernando, Peng Lee, Masashi Narita, William Muller, Jinsong Liu and Jian-Jun Wei
    Cancer Res January 15 2011 71 (2) 349-359; DOI:10.1158/0008-5472.CAN-10-2550

    Introduction of HMGA2 overexpression in ovarian surface epithelial cells is sufficient for a tumor transformation both in vitro and in vivo through regulation of epithelial to mesenchymal transition.

  • Molecular and Cellular Pathobiology
    p190RhoGEF (Rgnef) Promotes Colon Carcinoma Tumor Progression via Interaction with Focal Adhesion Kinase
    Hong-Gang Yu, Ju-Ock Nam, Nichol L. G. Miller, Isabelle Tanjoni, Colin Walsh, Lei Shi, Linda Kim, Xiao Lei Chen, Alok Tomar, Ssang-Taek Lim and David D. Schlaepfer
    Cancer Res January 15 2011 71 (2) 360-370; DOI:10.1158/0008-5472.CAN-10-2894

    Findings reveal a mechanism through which the pro-tumorigenic gastrointestinal hormone gastrin acts to promote invadopodia formation and invasive motility of colorectal carcinoma cells.

  • Molecular and Cellular Pathobiology
    The Tumor Suppressor Protein Menin Inhibits AKT Activation by Regulating Its Cellular Localization
    Yan Wang, Atsushi Ozawa, Shadia Zaman, Nijaguna B. Prasad, Settara C. Chandrasekharappa, Sunita K. Agarwal and Stephen J. Marx
    Cancer Res January 15 2011 71 (2) 371-382; DOI:10.1158/0008-5472.CAN-10-3221

    Restricting membrane translocation of AKT from the cytoplasm may have important implications for endocrine cancers and possibly other cancers where AKT dysregulation often occurs.

  • Molecular and Cellular Pathobiology
    Amiloride Modulates Alternative Splicing in Leukemic Cells and Resensitizes Bcr-AblT315I Mutant Cells to Imatinib
    Wen-Hsin Chang, Ta-Chih Liu, Wen-Kuang Yang, Chien-Chih Lee, Yi-Hsiung Lin, Tsai-Yun Chen and Jan-Gowth Chang
    Cancer Res January 15 2011 71 (2) 383-392; DOI:10.1158/0008-5472.CAN-10-1037

    Findings offer a mechanistic rationale based on modulation of alternate RNA splicing for testing of a common anti-hypertensive drug as an adjuvant therapy in leukemia.

  • Molecular and Cellular Pathobiology
    Phosphorylation of H2AX at Ser139 and a New Phosphorylation Site Ser16 by RSK2 Decreases H2AX Ubiquitination and Inhibits Cell Transformation
    Feng Zhu, Tatyana A. Zykova, Cong Peng, Jishuai Zhang, Yong-Yeon Cho, Duo Zheng, Ke Yao, Wei-Ya Ma, Andy T. Y. Lau, Ann M. Bode and Zigang Dong
    Cancer Res January 15 2011 71 (2) 393-403; DOI:10.1158/0008-5472.CAN-10-2012

    Findings define a new function for histone H2AX, a marker of DNA damage response and repair, that may inform the role of its phosphorylation in oncogenesis.

  • Molecular and Cellular Pathobiology
    A SP1/MIZ1/MYCN Repression Complex Recruits HDAC1 at the TRKA and p75NTR Promoters and Affects Neuroblastoma Malignancy by Inhibiting the Cell Response to NGF
    Nunzio Iraci, Daniel Diolaiti, Antonella Papa, Antonio Porro, Emanuele Valli, Samuele Gherardi, Steffi Herold, Martin Eilers, Roberto Bernardoni, Giuliano Della Valle and Giovanni Perini
    Cancer Res January 15 2011 71 (2) 404-412; DOI:10.1158/0008-5472.CAN-10-2627

    Findings establish a key pathway of clinical pathogenicity and aggressiveness in neuroblastoma, suggesting the use of HDAC inhibitors and nerve growth factor to treat MYCN-amplified tumors with the poorest prognosis.

Prevention and Epidemiology

  • Prevention and Epidemiology
    A Randomized Clinical Trial of the Effects of Supplemental Calcium and Vitamin D3 on Markers of Their Metabolism in Normal Mucosa of Colorectal Adenoma Patients
    Thomas U. Ahearn, Marjorie L. McCullough, W. Dana Flanders, Qi Long, Eduard Sidelnikov, Veronika Fedirko, Carrie R. Daniel, Robin E. Rutherford, Aasma Shaukat and Roberd M. Bostick
    Cancer Res January 15 2011 71 (2) 413-423; DOI:10.1158/0008-5472.CAN-10-1560

    Findings offer mechanstic evidence for calcium and vitamin D3 as chemopreventive agents against colorectal neoplasms, suggesting several modifiable, pre-neoplastic risk biomarkers for colorectal neoplasms.

Therapeutics, Targets, and Chemical Biology

  • Therapeutics, Targets, and Chemical Biology
    IL-6 Trans-Signaling in Formation and Progression of Malignant Ascites in Ovarian Cancer
    Chi-Wen Lo, Min-Wei Chen, Michael Hsiao, Shiuan Wang, Chi-An Chen, Sheng-Mou Hsiao, Jeng-Shou Chang, Tsung-Ching Lai, Stefan Rose-John, Min-Liang Kuo and Lin-Hung Wei
    Cancer Res January 15 2011 71 (2) 424-434; DOI:10.1158/0008-5472.CAN-10-1496

    Pathogenic effects of soluble receptor IL-6Rα in ovarian cancer might be specifically antagonized to enhance chemotherapeutic efficacy in ovarian cancer.

  • Therapeutics, Targets, and Chemical Biology
    Small Molecule Inhibition of GDC-0449 Refractory Smoothened Mutants and Downstream Mechanisms of Drug Resistance
    Gerrit J. P. Dijkgraaf, Bruno Alicke, Lasse Weinmann, Thomas Januario, Kristina West, Zora Modrusan, Dan Burdick, Richard Goldsmith, Kirk Robarge, Dan Sutherlin, Suzie J. Scales, Stephen E. Gould, Robert L. Yauch and Frederic J. de Sauvage
    Cancer Res January 15 2011 71 (2) 435-444; DOI:10.1158/0008-5472.CAN-10-2876

    Findings suggest tactics to circumvent acquired resistance to a Hedgehog pathway inhibitor that is currently in clinical development as an anticancer treatment.

  • Therapeutics, Targets, and Chemical Biology
    MEK1/2 Inhibitors AS703026 and AZD6244 May Be Potential Therapies for KRAS Mutated Colorectal Cancer That Is Resistant to EGFR Monoclonal Antibody Therapy
    Juyong Yoon, Kyoung-Hwa Koo and Kang-Yell Choi
    Cancer Res January 15 2011 71 (2) 445-453; DOI:10.1158/0008-5472.CAN-10-3058

    Findings describe a drug therapy that can attack tumors with K-ras mutations that are resistant to existing EGFR specific therapies.

  • Therapeutics, Targets, and Chemical Biology
    Combination Therapy with Vidaza and Entinostat Suppresses Tumor Growth and Reprograms the Epigenome in an Orthotopic Lung Cancer Model
    Steven A. Belinsky, Marcie J. Grimes, Maria A. Picchi, Hugh D. Mitchell, Chris A. Stidley, Yohannes Tesfaigzi, Meghan M. Channell, Yanbin Liu, Robert A. Casero , Jr., Stephen B. Baylin, Mathew D. Reed, Carmen S. Tellez and Thomas H. March
    Cancer Res January 15 2011 71 (2) 454-462; DOI:10.1158/0008-5472.CAN-10-3184

    This study offers new insights into how epigenetic therapy may affect different tumor cell populations and impact cell differentiation through activation of polycomb marked genes and pathways implicated in development.

  • Therapeutics, Targets, and Chemical Biology
    CCT241533 Is a Potent and Selective Inhibitor of CHK2 that Potentiates the Cytotoxicity of PARP Inhibitors
    Victoria E. Anderson, Michael I. Walton, Paul D. Eve, Katherine J. Boxall, Laurent Antoni, John J. Caldwell, Wynne Aherne, Laurence H. Pearl, Antony W. Oliver, Ian Collins and Michelle D. Garrett
    Cancer Res January 15 2011 71 (2) 463-472; DOI:10.1158/0008-5472.CAN-10-1252

    While encouraging the concept of combining CHK2 inhibition with genotxic anti-cancer drugs, this study also strongly supports the use of CHK2 inhibitors to potentiate the anticancer effects of PARP inhibitors, an exciting new modality for cancer treatment.

  • Therapeutics, Targets, and Chemical Biology
    A Novel Sialyltransferase Inhibitor Suppresses FAK/Paxillin Signaling and Cancer Angiogenesis and Metastasis Pathways
    Jia-Yang Chen, Yen-An Tang, Sin-Ming Huang, Hsueh-Fen Juan, Li-Wha Wu, Ying-Chieh Sun, Szu-Chi Wang, Kuan-Wei Wu, Gopula Balraj, Tzu-Ting Chang, Wen-Shan Li, Hung-Chi Cheng and Yi-Ching Wang
    Cancer Res January 15 2011 71 (2) 473-483; DOI:10.1158/0008-5472.CAN-10-1303

    Findings offer preclinical proof-of-concept that small molecule inhibitors of a glycoprotein modifying enzyme could offer a widely applicable strategy to treat advanced cancers.

  • Therapeutics, Targets, and Chemical Biology
    Peptides and Aptamers Targeting HSP70: A Novel Approach for Anticancer Chemotherapy
    Anne-Laure Rérole, Jessica Gobbo, Aurelie De Thonel, Elise Schmitt, Jean Paul Pais de Barros, Arlette Hammann, David Lanneau, Eric Fourmaux, Oleg Deminov, Olivier Micheau, Laurent Lagrost, Pierre Colas, Guido Kroemer and Carmen Garrido
    Cancer Res January 15 2011 71 (2) 484-495; DOI:10.1158/0008-5472.CAN-10-1443

    Lead compounds offer proof- of- concept for aptamer peptides that can exert immunogenic anti-tumor effects based on blockade of the central protein-folding chaperone molecule Hsp70.

  • Therapeutics, Targets, and Chemical Biology
    Eribulin Induces Irreversible Mitotic Blockade: Implications of Cell-Based Pharmacodynamics for In vivo Efficacy under Intermittent Dosing Conditions
    Murray J. Towle, Kathleen A. Salvato, Bruce F. Wels, Kimberley K. Aalfs, Wanjun Zheng, Boris M. Seletsky, Xiaojie Zhu, Bryan M. Lewis, Yoshito Kishi, Melvin J. Yu and Bruce A. Littlefield
    Cancer Res January 15 2011 71 (2) 496-505; DOI:10.1158/0008-5472.CAN-10-1874

    A mechanistically unique microtubule inhibitor in Phase III trials induces an irreversible mitotic block that contributes to its in vivo antitumor efficacy under intermittent dosing conditions.

  • Therapeutics, Targets, and Chemical Biology
    The BH3 Mimetic ABT-737 Induces Cancer Cell Senescence
    Jin H. Song, Karthikeyan Kandasamy, Marina Zemskova, Ying-Wei Lin and Andrew S. Kraft
    Cancer Res January 15 2011 71 (2) 506-515; DOI:10.1158/0008-5472.CAN-10-1977

    An important pro-apoptotic drug currently in human clinical trials is found to activate gene transcription, heighten DNA damage, and trigger senescence in cancer cells that are not susceptible to death induced by this agent, potentially expanding its effective use as a cancer therapy.

  • Therapeutics, Targets, and Chemical Biology
    Highly Specific Auto-Antibodies against Claudin-18 Isoform 2 Induced by a Chimeric HBcAg Virus-Like Particle Vaccine Kill Tumor Cells and Inhibit the Growth of Lung Metastases
    Thorsten Klamp, Jens Schumacher, Georg Huber, Christoph Kühne, Ulrich Meissner, Abderraouf Selmi, Thomas Hiller, Sebastian Kreiter, Jürgen Markl, Özlem Türeci and Ugur Sahin
    Cancer Res January 15 2011 71 (2) 516-527; DOI:10.1158/0008-5472.CAN-10-2292

    Findings describe a novel, chimeric bio-nanoparticle based vaccine that induces auto-antibodies directed against the native conformation of a pan-cancer target and demonstrating cytocidal and tumoricidal effector functions.

  • Therapeutics, Targets, and Chemical Biology
    CaM Kinase Kinase β-Mediated Activation of the Growth Regulatory Kinase AMPK Is Required for Androgen-Dependent Migration of Prostate Cancer Cells
    Daniel E. Frigo, Matthew K. Howe, Bryan M. Wittmann, Abigail M. Brunner, Ian Cushman, Qianben Wang, Myles Brown, Anthony R. Means and Donald P. McDonnell
    Cancer Res January 15 2011 71 (2) 528-537; DOI:10.1158/0008-5472.CAN-10-2581

    This study describes a pathogenic growth regulatory pathway in prostate cancer that suggests important novel targets for therapy.

  • Therapeutics, Targets, and Chemical Biology
    ROS and CHOP Are Critical for Dibenzylideneacetone to Sensitize Tumor Cells to TRAIL through Induction of Death Receptors and Downregulation of Cell Survival Proteins
    Sahdeo Prasad, Vivek R. Yadav, Jayaraj Ravindran and Bharat B. Aggarwal
    Cancer Res January 15 2011 71 (2) 538-549; DOI:10.1158/0008-5472.CAN-10-3121

    Drugs that can defeat resistance mechanisms to TRAIL may improve opportunities to exploit the anti-cancer properties of this cytokine.

Tumor and Stem Cell Biology

  • Tumor and Stem Cell Biology
    Microfluidic-Based Multiplex qRT-PCR Identifies Diagnostic and Prognostic microRNA Signatures in the Sera of Prostate Cancer Patients
    Felix Moltzahn, Adam B. Olshen, Lauren Baehner, Andrew Peek, Lawrence Fong, Hubert Stöppler, Jeffry Simko, Joan F. Hilton, Peter Carroll and Robert Blelloch
    Cancer Res January 15 2011 71 (2) 550-560; DOI:10.1158/0008-5472.CAN-10-1229

    MicroRNA signatures that can be detected in blood serum may allow definition of different risk-stratified patients with prostate cancer.

  • Tumor and Stem Cell Biology
    Chromosome Breakage Is Regulated by the Interaction of the BLM Helicase and Topoisomerase IIα
    Beatriz Russell, Saumitri Bhattacharyya, Jeremy Keirsey, April Sandy, Patrick Grierson, Erin Perchiniak, Juraj Kavecansky, Samir Acharya and Joanna Groden
    Cancer Res January 15 2011 71 (2) 561-571; DOI:10.1158/0008-5472.CAN-10-1727

    Results elucidate a DNA repair mechanism that is critical to maintain chromosome stability in cells, a deficiency which greatly increases cancer risk.

  • Tumor and Stem Cell Biology
    Decreased Expression and Androgen Regulation of the Tumor Suppressor Gene INPP4B in Prostate Cancer
    Myles C. Hodgson, Long-jiang Shao, Anna Frolov, Rile Li, Leif E. Peterson, Gustavo Ayala, Michael M. Ittmann, Nancy L. Weigel and Irina U. Agoulnik
    Cancer Res January 15 2011 71 (2) 572-582; DOI:10.1158/0008-5472.CAN-10-2314

    Findings strongly reinforce the concept that therapeutics which target Akt signaling are likely to be effective in blocking the growth of metastatic prostate cancer cells.

  • Tumor and Stem Cell Biology
    MicroRNA-616 Induces Androgen-Independent Growth of Prostate Cancer Cells by Suppressing Expression of Tissue Factor Pathway Inhibitor TFPI-2
    Stephanie Ma, Yuen Piu Chan, Pak Shing Kwan, Terence K. Lee, Mingxia Yan, Kwan Ho Tang, Ming Tat Ling, Juergen R. Vielkind, Xin-Yuan Guan and Kwok Wah Chan
    Cancer Res January 15 2011 71 (2) 583-592; DOI:10.1158/0008-5472.CAN-10-2587

    Findings reveal an interesting microRNA-regulated extracellular tumor suppressor pathway that is critical to support androgen-independent prostate cancers and amenable to therapeutic disruption.

  • Tumor and Stem Cell Biology
    Suppression of Colonic Polyposis by Homeoprotein CDX2 through its Nontranscriptional Function that Stabilizes p27Kip1
    Koji Aoki, Fumihiko Kakizaki, Hiromi Sakashita, Toshiaki Manabe, Masahiro Aoki and Makoto M. Taketo
    Cancer Res January 15 2011 71 (2) 593-602; DOI:10.1158/0008-5472.CAN-10-2842

    A novel non-transcriptional function of CDX2 plays a key role in tumor suppression through stabilization of p27Kip1.

  • Tumor and Stem Cell Biology
    Cytokine Receptor CXCR4 Mediates Estrogen-Independent Tumorigenesis, Metastasis, and Resistance to Endocrine Therapy in Human Breast Cancer
    Lyndsay V. Rhodes, Sarah P. Short, Nicole F. Neel, Virgilio A. Salvo, Yun Zhu, Steven Elliott, Yongkun Wei, Dihua Yu, Menghong Sun, Shannon E. Muir, Juan P. Fonseca, Melyssa R. Bratton, Chris Segar, Syreeta L. Tilghman, Tammy Sobolik-Delmaire, Linda W. Horton, Snjezana Zaja-Milatovic, Bridgette M. Collins-Burow, Scott Wadsworth, Barbara S. Beckman, Charles E. Wood, Suzanne A. Fuqua, Kenneth P. Nephew, Paul Dent, Rebecca A. Worthylake, Tyler J. Curiel, Mien-Chie Hung, Ann Richmond and Matthew E. Burow
    Cancer Res January 15 2011 71 (2) 603-613; DOI:10.1158/0008-5472.CAN-10-3185

    Findings describe a potentially important mechanism of resistance to endocrine therapies used widely in nearly all ER+ breast cancer patients, with implications on how to bypass this resistance mechanism.

  • Tumor and Stem Cell Biology | Free Article
    Breast Cancer Stem Cells Are Regulated by Mesenchymal Stem Cells through Cytokine Networks
    Suling Liu, Christophe Ginestier, Sing J. Ou, Shawn G. Clouthier, Shivani H. Patel, Florence Monville, Hasan Korkaya, Amber Heath, Julie Dutcher, Celina G. Kleer, Younghun Jung, Gabriela Dontu, Russell Taichman and Max S. Wicha
    Cancer Res January 15 2011 71 (2) 614-624; DOI:10.1158/0008-5472.CAN-10-0538

    Strategies aimed at interfering with the proposed cytokine loops may provide a means of targeting the cancer stem cell population.

Letter to the Editor

  • Letter to the Editor
    Statistical Design Considerations in Animal Studies Published Recently in Cancer Research
    Kenneth R. Hess
    Cancer Res January 15 2011 71 (2) 625-625; DOI:10.1158/0008-5472.CAN-10-3296

Correction

  • Correction
    Correction: Surface-Immobilized Aptamers for Cancer Cell Isolation and Microscopic Cytology
    Cancer Res January 15 2011 71 (2) 626-626; DOI:10.1158/0008-5472.CAN-10-4187

Back to top
PreviousNext
Cancer Research: 71 (2)
January 2011
Volume 71, Issue 2
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

Issue Highlights

  • Breast Cancer Stem Cells Are Regulated by Mesenchymal Stem Cells through Cytokine Networks
  • IL-6 Trans-Signaling in Formation and Progression of Malignant Ascites in Ovarian Cancer
  • The BH3 Mimetic ABT-737 Induces Cancer Cell Senescence

Jump to

  • Breaking Advances
  • Reviews
  • Perspective
  • Meeting Reports
  • Microenvironment and Immunology
  • Molecular and Cellular Pathobiology
  • Prevention and Epidemiology
  • Therapeutics, Targets, and Chemical Biology
  • Tumor and Stem Cell Biology
  • Letter to the Editor
  • Correction
Advertisement
  • Most Cited
  • Most Read
Loading
  • Towards Multidrug Adaptive Therapy
  • MEK Inhibition Synergizes with Statins for Cancer Treatment
  • IL1β Promotes Immune Suppression in Pancreatic Cancer
  • Multiple Primary Cancer Penetrance for TP53
  • Metabolomic Gradients in Glioblastoma Models
More...
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement